Clover Health Investments, Corp. (CLOV)
| Market Cap | 1.79B +5.4% |
| Revenue (ttm) | 2.21B +48.7% |
| Net Income | -56.94M |
| EPS | -0.11 |
| Shares Out | 526.68M |
| PE Ratio | n/a |
| Forward PE | 34.25 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,080,215 |
| Open | 3.400 |
| Previous Close | 3.470 |
| Day's Range | 3.283 - 3.520 |
| 52-Week Range | 1.580 - 3.920 |
| Beta | 2.45 |
| Analysts | Buy |
| Price Target | 3.15 (-7.08%) |
| Earnings Date | May 6, 2026 |
About CLOV
Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for physicians to detect, identify, and manage chronic diseases. The company was founded in 2014 and is based in Wilmington, Delaware.
Financial Performance
In 2025, Clover Health Investments's revenue was $1.92 billion, an increase of 40.33% compared to the previous year's $1.37 billion. Losses were -$85.55 million, 98.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for CLOV stock is "Buy." The 12-month stock price target is $3.15, which is a decrease of -7.08% from the latest price.
News
Clover Health Investments Earnings Call Transcript: Q1 2026
Q1 2026 saw 51% membership growth, $27M GAAP net income, and 62% revenue growth year-over-year. Gross profit rose 47%, with strong retention, clinical engagement, and scale efficiencies supporting a positive outlook for 2026.
Clover Health Investments Earnings release: Q1 2026
Clover Health Investments released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Clover Health Investments Slides: Q1 2026
Clover Health Investments has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Clover Health Investments Quarterly report: Q1 2026
Clover Health Investments has published its Q1 2026 quarterly earnings report on May 6, 2026.
Clover Health Reports First Quarter 2026 Results
Business Highlights: Delivered positive GAAP Net Income in the first quarter of 2026, with strong performance across key metrics: Total revenues, Adjusted EBITDA, and Consolidated Gross Profit Market-...
Clover Health Investments Proxy statement: Proxy filing
Clover Health Investments filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Clover Health Investments Proxy statement: Proxy filing
Clover Health Investments filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Clover Health to Report First Quarter 2026 Financial Results on May 6, 2026
WILMINGTON, Del., April 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial re...
Clover Health Empowers Members to Take Charge of Their Health Data Through HealthEx Partnership
WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to bringing ...
Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026
WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover” or the “Company”), a physician enablement company committed to bringing access to great h...
Clover Health price target lowered to $3.20 from $3.70 at Canaccord
Canaccord lowered the firm’s price target on Clover Health (CLOV) to $3.20 from $3.70 and keeps a Buy rating on the shares. The firm said Clover took some lumps in…
Clover Health’s Counterpart Assistant associated with decrease in flu events
Clover Health’s (CLOV) wholly owned subsidiary Counterpart Health, an AI-powered physician-enablement platform, released a whitepaper which finds that patients whose primary care physicians used Count...
Primary Care Physician Use of Counterpart Assistant Associated with 18%–22% Fewer Flu-Related Acute Care Events Among COPD and CHF Patients
SAN FRANCISCO, March 19, 2026 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or t...
Clover Health Investments Transcript: Leerink Global Healthcare Conference 2026
AI-driven Medicare Advantage plan reports strong growth, 95%+ retention, and expects GAAP profitability in 2026. Technology platform enables earlier diagnoses and better outcomes, with 70% of members covered by its software. Expansion into SaaS for external providers is underway.
UPDATED – Moving from Pledge to Production, Clover Health is Now Live on Kno2, Participating in Recently Announced Federal Interoperability Initiatives
NOTICE: This is an updated version of a press release originally issued March 4, 2026 by Clover Health Investments, Corp. (Nasdaq: CLOV). Language has been updated to further refine the description of...
Clover Health Investments Slides: Investor presentation
Clover Health Investments has posted slides in relation to its latest quarterly earnings report, which was published on March 10, 2026.
Clover Health becomes first player live on CMS Aligned Network
Clover Health (CLOV) Investments announced a collaboration enabling Clover Health to be the first payer live on a CMS Aligned Network and TEFCA. Clover is demonstrating that nationwide, interoperable ...
Clover Health Moves from Pledge to Production, Becomes The First Payer Live on a CMS Aligned Network
WILMINGTON, Del., March 04, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to bringing ...
Clover Health price target lowered to $2.75 from $3 at UBS
UBS analyst Jonathan Yong lowered the firm’s price target on Clover Health (CLOV) to $2.75 from $3 and keeps a Neutral rating on the shares.
Clover Health reports Q4 EPS (10c), consensus (5c)
Reports Q4 revenue $487.7M, consensus $467.06M. “Our results in 2025 validate the scalability of our differentiated model, despite some headwinds during the year,” said Clover Health (CLOV) CEO Andrew...
Clover Health Investments Earnings Call Transcript: Q4 2025
Achieved full year Adjusted EBITDA profitability in 2025 with 38% membership growth and strong cost control. 2026 guidance targets first full year of GAAP net income profitability, 46% membership growth, and continued operating leverage, supported by a four-star payment year and technology-driven model.
Clover Health Investments Annual report: Q4 2025
Clover Health Investments has published its Q4 2025 annual report on February 26, 2026.
Clover Health Investments Earnings release: Q4 2025
Clover Health Investments released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Clover Health Investments Slides: Q4 2025
Clover Health Investments has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.
Clover Health Reports Fourth Quarter & Full Year 2025 Results; Provides Full Year 2026 Guidance
Business Highlights: Generated full year 2025 Adjusted EBITDA profitability while growing membership by 38% and Insurance revenue by 41% year-over-year Achieved industry-leading 2026 AEP growth of 53%...